A Diagnostics & Imaging Week

Meridian Bioscience (Cincinnati) said it has filed a shelf registration statement on Form S-3 with the Securities and Exchange Commission (SEC). This registration statement replaces the company's existing shelf registration statement originally filed in September 2003, which was scheduled to expire on Dec. 1, Meridian noted.

This unlimited shelf registration includes common stock, preferred stock, debt and other types of securities and automatically became effective upon filing.

The company said it may publicly offer these securities from time to time at prices and on terms to be determined at the time of the offering. The specific terms of a future offering, if any, will be provided in a supplemental prospectus relating to any such offering.

The company said it would use the proceeds from any offerings under the registration statement for a variety of purposes including repayment or refinancing of indebtedness, working capital, capital expenditures, acquisitions, or other business opportunities and general corporate purposes.

The company said the shelf registration would provide flexibility for the possible sale of securities when market conditions are attractive. The company says it has no immediate plans to draw upon the registration.

Meridian makes diagnostic test kits, purified reagents and related products and offers biopharmaceutical enabling technologies. These products are designed to provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as gastrointestinal, viral and respiratory infections.